0000000001010609

AUTHOR

Angelo Maria Patti

showing 62 related works from this author

Pharmacotherapy for gestational diabetes

2018

Introduction: Gestational diabetes mellitus (GDM) represents impaired carbohydrate metabolism during pregnancy and is characterized by progressive insulin resistance and compensatory hyperinsulinaemia. If inadequately treated, it may lead to fetal macrosomia and other adverse outcomes. Areas covered: In this review, the authors summarize the current evidence from studies on the use of insulin and other agents for the treatment of women with GDM. Expert opinion: Lifestyle management is of paramount importance for the treatment of GDM. In pharmacotherapy, insulin remains the long-established mainstay of treatment. NPH (Neutral Protamine Hagedorn) and soluble human insulin have long been estab…

medicine.medical_specialtyinsulinlifestyleendocrine system diseasesmedicine.medical_treatment030209 endocrinology & metabolismCarbohydrate metabolism03 medical and health sciences0302 clinical medicineInsulin resistancePharmacotherapyPregnancyInternal medicineHumansMedicineHypoglycemic AgentsPharmacology (medical)030212 general & internal medicineDipeptidyl-Peptidase IV InhibitorsPharmacologyDipeptidyl-Peptidase IV InhibitorsPregnancytherapybusiness.industryInsulinnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseincretinPregnancy ComplicationPregnancy ComplicationsGestational diabetesDiabetes GestationalEndocrinologyGestational diabeteDipeptidyl-Peptidase IV InhibitorFemalebusiness
researchProduct

GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms

2018

Type 2 diabetes mellitus (T2DM) is a metabolic condition with an elevated impact on cardiovascular (CV) risk. The innovative therapeutic approaches for T2DM - incretin-based therapies (IBTs), including glucagon-like peptide 1 (GLP-1) receptor agonists, have become popular and more widely used in recent years. The available scientific data from clinical studies and clinical practice highlights their beyond glucose-lowering effects, which is achieved without any increase in hypoglycaemia. The former effects include reduction in body weight, lipids, blood pressure, inflammatory markers, oxidative stress, endothelial dysfunction, and subclinical atherosclerosis, thus reducing and potentially pr…

Blood GlucoseCardiometabolic parameterGlucagon-Like PeptidesIncretin030209 endocrinology & metabolism030204 cardiovascular system & hematologyBioinformaticsIncretinsGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsEndothelial dysfunctionMolecular BiologyGlucagon-like peptide 1 receptorLiraglutidebusiness.industryType 2 Diabetes MellitusLiraglutideCardiovascular riskmedicine.diseasePlaque AtheroscleroticType 2 diabetes mellituBlood pressureDiabetes Mellitus Type 2Cardiovascular DiseasesMetabolic control analysisGlucagon-like peptide 1 receptor agonistMolecular Medicinebusinessmedicine.drugBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
researchProduct

Relationship among Body Composition, Adipocytokines, and Irisin on Exercise Capacity and Quality of Life in COPD: A Pilot Study

2022

Adipose tissue is an endocrine organ that interferes with the severity of chronic obstructive pulmonary disease (COPD). Although inflammatory markers, body composition, and nutritional status have a significant impact on pulmonary function, the real contribution of adipocytokines and myokines in COPD is still controversial. We aimed to evaluate the role played by the body composition, leptin, adiponectin, haptoglobin, and irisin on the functional exercise capacity, respiratory function, and quality of life (QoL) in COPD. In 25 COPD (20% GOLD-1; 60% GOLD-2; 20% GOLD-3) patients and 26 matched control subjects, we find that leptin, total adiponectin and haptoglobin are significantly increased…

adipocytokines; adiponectin; body composition; COPD; haptoglobin; irisin; leptin; quality of life; 6 min walking testMolecular BiologyBiochemistryBiomolecules
researchProduct

Leptin and TGF-β1 Downregulate PREP1 Expression in Human Adipose-Derived Mesenchymal Stem Cells and Mature Adipocytes

2021

International audience; Adipose tissue is widely recognized as an extremely active endocrine organ producing adipokines as leptin that bridge metabolism and the immune system. Pre-B-cell leukemia homeobox (Pbx)-regulating protein-1 (PREP1) is a ubiquitous homeodomain transcription factor involved in the adipogenic differentiation and insulin-sensitivity processes. Leptin, as pleiotropic adipokine, and TGF-β, known to be expressed by primary pre-adipocytes [adipose-derived stem cells (ASCs)] and mature differentiated adipocytes, modulate inflammatory responses. We aimed to assess for the first time if leptin and TGF-β interfere with PREP1 expression in both ASCs and mature differentiated adi…

0301 basic medicinePREP1QH301-705.5adipocytes[SDV]Life Sciences [q-bio]Adipose tissueAdipokine030209 endocrinology & metabolism610 Medicine & healthBiologyadipocyteleptinTGF-beta1Cell and Developmental Biology03 medical and health sciences0302 clinical medicineDownregulation and upregulationTLR4Biology (General)610 Medicine & healthReceptorOriginal ResearchLeptinMesenchymal stem cellCell BiologyCell biologyadipose tissueimmune system030104 developmental biologyadipocyte-derived stem cellsAdipogenesisStem celladipocyte-derived stem cellDevelopmental Biology
researchProduct

Pharmacotherapy for gestational diabetes mellitus: still insulin, or what about sulfonylureas?

2018

Randomized trials have not focused on neonatal complications of glyburide for women with gestational diabetes.To compare oral glyburide vs subcutaneous insulin in prevention of perinatal complications in newborns of women with gestational diabetes.The Insulin Daonil trial (INDAO), a multicenter noninferiority randomized trial conducted between May 2012 and November 2016 (end of participant follow-up) in 13 tertiary care university hospitals in France including 914 women with singleton pregnancies and gestational diabetes diagnosed between 24 and 34 weeks of gestation.Women who required pharmacologic treatment after 10 days of dietary intervention were randomly assigned to receive glyburide …

AdultBlood Glucosemedicine.medical_specialtyendocrine system diseasesInjections Subcutaneousmedicine.medical_treatmentAdministration Oral030209 endocrinology & metabolism.OverweightInfant Newborn DiseasesFetal Macrosomia03 medical and health sciences0302 clinical medicinePharmacotherapyInsulin resistancePregnancyInternal medicineGlyburidemedicineHumansHypoglycemic AgentsInsulin030212 general & internal medicineFamily historyHyperbilirubinemiabusiness.industryInsulinInfant NewbornPregnancy Outcomenutritional and metabolic diseasesType 2 Diabetes MellitusGeneral Medicinemedicine.diseaseHypoglycemiafemale genital diseases and pregnancy complicationsGestational diabetesDiabetes GestationalEditorialEndocrinologyFemalemedicine.symptomMetabolic syndromebusinessAnnals of Translational Medicine
researchProduct

Smoking and small, dense low-density lipoproteins.

2013

Lipoproteins LDLMetabolic SyndromeSleep Apnea ObstructiveText miningbusiness.industryLow densityMedicineHumansSmoking small dense low-density lipoproteins.Computational biologyCardiology and Cardiovascular MedicinebusinessAngiology
researchProduct

Future perspectives of the pharmacological management of diabetic dyslipidemia

2019

Introduction: Diabetic dyslipidemia is frequent among patients with type 2 diabetes mellitus (T2DM) and is characterized by an increase in triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), and small-dense (atherogenic) particles, and by a decrease in low high-density lipoprotein cholesterol (HDL-C) and apolipoprotein (Apo) A1 that are strongly related to insulin resistance. The increased flux of free fatty acids from adipose tissue to the liver aggravates hepatic insulin resistance and promotes all of aspects of the dyslipidemic state. Areas covered: Statins are the first-line agents for treatment while other lipid-lowering drugs (ezetimibe, fibrate and proprotein convertase…

medicine.medical_specialtyApolipoprotein Bmedicine.drug_classglucagon like peptide-1 receptor agonist (GLP-1RA)Fibrate030226 pharmacology & pharmacystatins03 medical and health sciences0302 clinical medicineInsulin resistanceEzetimibeInternal medicinemedicineHumansHypoglycemic AgentsPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsOmega 3 fatty acidDyslipidemiasHypolipidemic Agentsfibratebiologybusiness.industrydyslipidemianutritional and metabolic diseasesType 2 Diabetes MellitusGeneral MedicineLipidmedicine.diseasesodium/glucose cotransporter 2 inhibitors (SGLT-2is)LipidsEndocrinologyDiabetes Mellitus Type 2Cardiovascular Diseases030220 oncology & carcinogenesisDipeptidyl peptidase-4 inhibitors (DPP-4is)Dietary Supplementsbiology.proteinKexinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistancebusinessDyslipidemiamedicine.drugezetimibeproprotein convertase subtilisin/kexin type 9 (PCSK9)
researchProduct

Advances in pharmacological treatment of type 1 diabetes during pregnancy.

2019

Introduction: In women with type 1 diabetes mellitus (T1DM), pregnancy is associated with a potential risk of maternal, foetal and neonatal outcomes. Stringent metabolic control is required to improve these outcomes. Areas covered: In this review, the authors summarise the current evidence from studies on the pharmacological therapy and on monitoring of T1DM during pregnancy. The authors also discuss the use of new technologies to improve therapeutic management and patient compliance. Expert opinion: Pre-conception counselling is essential in T1DM to minimise pregnancy risks. Pregnancy in T1DM is always considered a high-risk pregnancy. During pregnancy, the target haemoglobin A1C (HbA1c) i…

Blood Glucoseendocrine system diseasesPregnancy in DiabeticsDiabetic complicationBioinformaticsPharmacological treatmenttype 1 diabetes mellitu03 medical and health sciences0302 clinical medicinePregnancymedicineHumansHypoglycemic AgentsInsulinPharmacology (medical)PharmacologyType 1 diabetesPregnancyPotential riskbusiness.industryCesarean Sectionnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseHypoglycemiaglycaemic controlDiabetes Mellitus Type 1Neonatal outcomes030220 oncology & carcinogenesisMetabolic control analysisFemalebusiness030217 neurology & neurosurgeryExpert opinion on pharmacotherapy
researchProduct

Nutraceuticals in Lipid-Lowering Treatment

2014

Lipid-lowering drugs may cause adverse effects and, although lipid targets may be achieved, a substantial residual cardiovascular (CV) risk remains. Treatment with agents mimicking proteins present in the body, such as incretin-based therapies, provided promising results. However, in order to improve lipids and CV risk, lifestyle measures remain important. Some researchers focused on nutraceuticals that may beneficially affect metabolic parameters and minimize CV risk. Chitosan, a dietary fiber, can regulate lipids with benefit on anthropometric parameters. The beneficial properties of dietary supplements (such as green tea extract, prebiotics, plant sterols, and stanols) on plasma lipids,…

Dietary Fibermedicine.medical_treatmentGreen tea extractPharmacologyChitosanchemistry.chemical_compoundNutraceuticallipidRisk FactorsmedicineAnimalsHumansAdverse effectDyslipidemiasHypolipidemic AgentsChitosanTraditional medicinebusiness.industryMedicine (all)InsulinlipoproteinLipidsClinical trialTreatment OutcomeBlood pressurechemistryCardiovascular Diseasesdietary supplementDietary SupplementsnutraceuticalLipid loweringCardiology and Cardiovascular MedicinebusinessBiomarkersAngiology
researchProduct

Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome.

2021

Background: Metabolic syndrome is a clinical condition that deserves special attention because it puts the individual at high cardiovascular risk, especially heart attack and stroke. Considering precision medicine, it would be advisable to evaluate the individual cardio-metabolic risk by estimating the coexistence of risk factors (abdominal obesity, low level of High-Density Lipoprotein Cholesterol, High Triglycerides, and small dense Low-Density Lipoproteins sub-classes, hypertension, and elevated fasting glycemia), which could engrave on metabolism increasing cardiovascular mortality. Objective: To identify genetic and epigenetic biomarkers may assist in the possibility of helping follow…

EpigenomicsBioinformaticsEpigenesis GeneticGeneticDrug DiscoverymedicineHumansEpigeneticsAbdominal obesityPharmacologyInflammationMetabolic Syndromebusiness.industryEpigeneticEpigenomeDNA MethylationPrecision medicinemedicine.diseasePrognosisManagementDNA methylationHuman genomePersonalized medicineMetabolic Pathwaysmedicine.symptomMetabolic syndromebusinessBiomarkersCurrent pharmaceutical design
researchProduct

Cilostazol and atherogenic dyslipidemia: a clinically relevant effect

2011

Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication. However, beyond its antiplatelet and vasodilator properties, cilostazol seems to have significant effects on atherogenic dyslipidemia.The effects of cilostazol on plasma lipids, lipoproteins, apolipoproteins and postprandial lipemia are reviewed. A literature search (using Medline and Scopus) was performed up to 24 October 2010. The authors also manually reviewed the references of selected articles for any pertinent material.Cilostazol is able to significantly lower plasma triglyceride levels, with a concomitant increase in high-density lipoprot…

medicine.medical_specialtyApolipoprotein BTetrazolescilostazol atherogenic dyslipidemiaPhosphodiesterase 3 InhibitorsPeripheral Arterial Diseasechemistry.chemical_compoundDiabetes mellitusInternal medicineHumansMedicinePharmacology (medical)DyslipidemiasPharmacologymedicine.diagnostic_testbiologybusiness.industryCholesterolGeneral MedicineAtherosclerosismedicine.diseaseLipidsCyclic Nucleotide Phosphodiesterases Type 3Intermittent claudicationCilostazolCilostazolPostprandialEndocrinologyDiabetes Mellitus Type 2chemistrybiology.proteinlipids (amino acids peptides and proteins)medicine.symptombusinessLipid profileLipoproteinmedicine.drug
researchProduct

Impact of Glucose-Lowering Medications on Cardiometabolic Risk in Type 2 Diabetes

2019

Type 2 Diabetes Mellitus (T2DM) is associated with a high risk of atherosclerotic cardiovascular (CV) disease. Contributing pathophysiologic factors include endothelial dysfunction caused by excessive production of reactive oxygen species (ROS), increased activity of nuclear factor kB (NFkB), altered macrophage polarization, and reduced synthesis of endothelial progenitor cells (EPC). Consequently, there can be a potentially rapid progression of the atherosclerotic disease with a higher propensity to unstable plaque, leading to increased cardiovascular mortality. Management is aimed at prevention, early diagnosis, and treatment of hyperglycemia and vascular complications. Innovative therape…

medicine_pharmacology_otherCardiometabolic riskGlucose loweringmedicine.medical_specialtybusiness.industryInternal medicinemedicineType 2 Diabetes MellitusType 2 diabetesmedicine.diseasebusiness
researchProduct

Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia

2017

Several risk factors such as abnormality of lipid metabolism (e.g. high levels of low-density lipoprotein cholesterol (LDL-C), elevated triglycerides and low levels of high-density lipoprotein cholesterol (HDL-C)) play a central role in the aetiology of cardiovascular disease (CVD). Nutraceutical combination together with a cholesterol- lowering action, when associated with suitable lifestyle, should furnish an alternative to pharmacotherapy in patients reporting statin-intolerance and in subjects at low cardiovascular risk. The present review is focused on nutraceuticals and their synergetic combinations demonstrating a beneficial effect in the management of dyslipidaemia. Several nutraceu…

0301 basic medicineDyslipidaemiaCombination therapyLow density lipoprotein cholesterol030204 cardiovascular system & hematologyReductaseBiologyPharmacology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNutraceuticalBerberineDrug DiscoverymedicineRed yeast riceHumansEndothelial dysfunctionEndothelial dysfunctionDyslipidemiasCarotidDietary SupplementPharmacologyCholesterolLipid metabolismLipidCardiovascular riskmedicine.diseaseLipidsIntima media thickne030104 developmental biologyDyslipidemiachemistryDietary SupplementsDrug Therapy Combinationlipids (amino acids peptides and proteins)NutraceuticalHumanCurrent Pharmaceutical Design
researchProduct

Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study.

2014

Background Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) analog, has several non- glycemic properties, but its effect on carotid intima-media thickness (IMT), a recognized marker of subclinical atherosclerosis, is still unknown. Methods A prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history of coronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by color doppler ultrasound. Results After 8 months, fasting glucose decreased by 2.1 mmol/l and HbA1c by 1.9% (p < 0.01 for all). Liraglutide reduced total-cholesterol and triglycerides by 10%, and LDL-cholesterol by 19%, whereas HDL-cholester…

Malemedicine.medical_specialtyEndocrinology Diabetes and MetabolismPilot ProjectsType2 diabetesType 2 diabetesCarotid Intima-Media ThicknessCoronary artery diseaseGlucagon-Like Peptide 1Internal medicineDiabetes mellitusLiraglutide Carotid intima-media thickness Cardiovascular risk Type2 diabetesmedicineHumansHypoglycemic AgentsProspective Studiescardiovascular diseasesProspective cohort studyGlycemicAgedOriginal Investigationbusiness.industryLiraglutideLiraglutideMiddle Agedmedicine.diseaseCardiovascular risk3. Good healthMetforminEndocrinologyIntima-media thicknessDiabetes Mellitus Type 2Cardiologycardiovascular systemFemalebusinessCardiology and Cardiovascular Medicinemedicine.drug
researchProduct

The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes

2020

ABSTRACT Introduction The dipeptidyl peptidase-4 inhibitors (DPP-4is), which belong to the class of incretin-based medications, are recommended as second or third-line therapies in guidelines for the management of type 2 diabetes mellitus. They have a favorable drug tolerability and safety profile compared to other glucose-lowering agents. Objective This review discusses data concerning the use of DPP-4is and their cardiovascular profile, and gives an updated comparison with the other oral glucose-lowering medications with regards to safety and efficacy. Currently available original studies, abstracts, reviews articles, systematic reviews and meta-analyses were included in the review. Discu…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismIncretin030209 endocrinology & metabolismType 2 diabetesSaxagliptinLinagliptinIncretins03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicinemedicineHumansHypoglycemic AgentsVildagliptinDipeptidyl-Peptidase IV InhibitorsPancreatitiHypoglycemic Agentbusiness.industryPancreatic NeoplasmIncretinmedicine.diseasePancreatic NeoplasmsTreatment Outcome030104 developmental biologyDiabetes Mellitus Type 2PancreatitischemistryTolerabilitySitagliptinDipeptidyl-Peptidase IV InhibitorbusinessAlogliptinHumanmedicine.drugMetabolism
researchProduct

Natural approaches in metabolic syndrome management

2017

Metabolic syndrome (MetS) is characterized as a group of cardiometabolic risk factors that raise the risk for heart disease and other health problems, such as diabetes mellitus and stroke. Treatment strategies include pharmacologic interventions and supplementary (or "alternative") treatments. Nutraceuticals are derived from food sources (isolated nutrients, dietary supplements and herbal products) that are purported to provide health benefits, in addition to providing basic nutritional value. Nutraceuticals are claimed to prevent chronic diseases, improve health, delay the aging process, increase life expectancy, and support the structure and function of the body. The study of the benefici…

Polyphenolmedicine.medical_specialtyHeart diseaseOmega-3 fatty acid030204 cardiovascular system & hematologyVitamin03 medical and health sciences0302 clinical medicineNutraceuticalmetabolicDiabetes mellitusMacroelementmedicineIn patient030212 general & internal medicineDosingIntensive care medicineStrokepolyphenolsmetabolic syndrome managementnutraceuticalsomega-3 fatty acidsbusiness.industryMedicine (all)General MedicinevitaminsCardiovascular risksyndromemedicine.diseaseMetabolic syndromeBiotechnologymacroelementsLife expectancyNutraceuticalMetabolic syndromebusinessState of the Art PapermanagementArchives of Medical Science
researchProduct

Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6…

2019

The objective was to evaluate the effects of 6 months of supplementation with Altilix&reg

0301 basic medicineSettore MED/09 - Medicina Internacynaragenetic structuresPlacebo-controlled study030204 cardiovascular system & hematologySettore BIO/09 - FisiologiaGastroenterology0302 clinical medicineDiabetes mellitusimmune system diseasescardiovascular diseasehemic and lymphatic diseasesBrachial arteryLuteolinNutrition and Dieteticsdiabetes mellituFatty liverhemic and immune systemsDietary supplementsMetabolic syndromeCardiovascular diseasesLivertype 2diabetes mellitusChlorogenic Acidlcsh:Nutrition. Foods and food supplymedicine.medical_specialtyWaistlcsh:TX341-641chemical and pharmacologic phenomenaCynaraPlacebometabolic syndromedietary supplements03 medical and health sciencesDouble-Blind MethodInternal medicineDiabetes mellitusmedicine.arterymedicinebusiness.industrynon-alcoholic fatty liver diseasemedicine.diseasecardiovascular diseases030104 developmental biologydietary supplementSteatosisMetabolic syndromebusinessFood ScienceNon-alcoholic fatty liver disease
researchProduct

Novel therapeutical approaches to managing atherosclerotic risk

2021

Atherosclerosis is a multifactorial vascular disease that leads to inflammation and stiffening of the arteries and decreases their elasticity due to the accumulation of calcium, small dense Low Density Lipoproteins (sdLDL), inflammatory cells, and fibrotic material. A review of studies pertaining to cardiometabolic risk factors, lipids alterations, hypolipidemic agents, nutraceuticals, hypoglycaemic drugs, atherosclerosis, endothelial dysfunction, and inflammation was performed. There are several therapeutic strategies including Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) inhibitors, inclisiran, bempedoic acid, Glucagon-Like Peptide-1 Receptor agonists (GLP-1 RAs), and nutraceuticals t…

QH301-705.5InflammationReview030204 cardiovascular system & hematologyPharmacologyCatalysisInorganic Chemistry03 medical and health sciences0302 clinical medicineLipid oxidationmedicineAnimalsHumans030212 general & internal medicineMolecular Targeted TherapyPhysical and Theoretical ChemistryEndothelial dysfunctionBiology (General)Molecular BiologyQD1-999SpectroscopyInnovative therapiesMolecular signalingVascular diseasebusiness.industryPCSK9Organic ChemistryGeneral MedicineProprotein convertasemedicine.diseaseAtherosclerosisComputer Science ApplicationsManagementChemistryInflammationsAtheromaOxidative stressHypolipidemic Agentslipids (amino acids peptides and proteins)Nutraceuticalsmedicine.symptombusiness
researchProduct

The effect of bergamot on dyslipidemia

2016

Abstract Background Statins are the most common used lipid lowering drugs but they may cause adverse effects and despite their well-established therapeutic benefits residual cardiovascular (CV) risk remains. The use of other lipid lowering drugs and nutraceuticals alone or as add-on lipid-modifying therapy can be an option in such cases. Several studies have reported health-related properties of the Citrus fruits, among which bergamot (Citrus bergamia Risso) differs from others by particularly high content of certain compounds. Purpose This narrative review summarizes the current evidence on the effects of bergamot on lipid parameters based on studies involving animals and humans. Main evid…

3003CitrusFuture studiesBergamotPharmaceutical Science030204 cardiovascular system & hematologyBioinformatics01 natural sciences03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNutraceuticalDrug DiscoverymedicineAnimalsHumansAdverse effectDyslipidemiasHypolipidemic AgentsFlavonoidsPharmacologyPlant ExtractsChemistryCholesterolMedicine (all)Drug Discovery3003 Pharmaceutical ScienceCardiovascular riskComplementary and Alternative Medicine2708 Dermatologymedicine.disease0104 chemical sciences010404 medicinal & biomolecular chemistryDyslipidemiaComplementary and alternative medicineBiochemistryLDL cholesterolCitrus bergamiaMolecular MedicineNarrative reviewLipid loweringDyslipidemiaPhytomedicine
researchProduct

Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus

2021

Diabetes represents the leading risk factor for the development of cardiovascular disease (CVD). Chronic hyperglycemia and/or acute post-prandial changes in blood glucose determine an increase in reactive oxygen species (ROS), which play a fundamental role in endothelial dysfunction and in the nuclear transport of pro-atherogenic transcription factors that activate the "inflammasome". In addition, the glycemic alteration favors the formation and stabilization of atherosclerotic plaque through the mechanism of non-enzymatic glycation of different molecules, with the establishment of the so-called "advanced glycosylation end products" (AGE). Laboratory information provided by the level of bio…

0301 basic medicineBlood GlucoseNovel biomarkersDisease030204 cardiovascular system & hematologyBioinformatics03 medical and health scienceschemistry.chemical_compound0302 clinical medicineGlycationRisk FactorsDiabetes mellitusType 2 diabetes mellitusMedicineHumansEndothelial dysfunctionRisk factorMolecular BiologyGlycemicInflammationGlycationbusiness.industryType 2 Diabetes Mellitusmedicine.diseaseCardiovascular risk030104 developmental biologychemistryDiabetes Mellitus Type 2Cardiovascular DiseasesOxidative stressMolecular MedicineAdvanced glycation end-productbusinessReactive Oxygen SpeciesBiomarkers
researchProduct

Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes

2020

Type 2 Diabetes Mellitus (T2DM) is associated with a high risk of atherosclerotic cardiovascular (CV) disease. Among the well-known pathophysiologic factors, crucial roles are played by endothelial dysfunction (caused by oxidative stress and inflammation hyperglycemia-linked), increased activity of nuclear factor kB, altered macrophage polarization, and reduced synthesis of resident endothelial progenitor cells. As consequence, a potentially rapid progression of the atherosclerotic disease with a higher propensity to unstable plaque is arguable, finally leading to significantly increased cardiovascular mortality. Main managements are focused on both prevention and early diagnosis, by target…

cardiovascular riskcardiovascular risk; dipeptidyl peptidase-4 inhibitors; glucagon like peptide-1 receptor agonists; sodium glucose cotransporter-2 inhibitors; type 2 diabetes mellitustype 2 diabetes mellitusglucagon like peptide-1 receptor agonistslcsh:Medicine030209 endocrinology & metabolismInflammationType 2 diabetesDiseaseReview030204 cardiovascular system & hematologyHypoglycemiaBioinformaticsmedicine.disease_cause03 medical and health sciences0302 clinical medicinemedicineEndothelial dysfunctionAdverse effectbusiness.industrylcsh:RType 2 Diabetes MellitusGeneral Medicinemedicine.diseasesodium glucose cotransporter-2 inhibitorsmedicine.symptombusinessdipeptidyl peptidase-4 inhibitorsOxidative stressJournal of Clinical Medicine
researchProduct

Effects of Chitosan on Plasma Lipids and Lipoproteins

2014

Chitosan can favorably modulate plasma lipids, but the available data are not conclusive. We evaluated the effect of chitosan on plasma lipids and lipoproteins in 28 patients with plasma triglyceride levels &gt;150 mg/dL (mean age: 63 ± 12 years), not taking other lipid-lowering agents. All patients received a chitosan derived from fungal mycelium (Xantonet, Bromatech, Italy) at a fixed dose of 125 mg/d in addition to their current medications for 4 months. Polyacrylamide gel electrophoresis was used to measure low-density lipoprotein (LDL) subclasses. After treatment, total cholesterol reduced by 8%, LDL cholesterol by 2%, and triglycerides by 19%, with a concomitant 14% increase in high-…

Malechitosan; lipids; lipoproteins; therapymedicine.medical_specialtyFuture studiesPilot ProjectsFixed doseBody Mass IndexChitosanchemistry.chemical_compoundlipidInternal medicinePlasma lipidsmedicineHumansProspective StudiesPolyacrylamide gel electrophoresisTriglyceridesHypertriglyceridemiaLdl cholesteroltherapybusiness.industryAnticholesteremic AgentslipoproteinMiddle AgedLipoproteins LDLCholesterolEndocrinologychemistryConcomitantFemalelipids (amino acids peptides and proteins)Waist CircumferencechitosanLipoproteins HDLCardiology and Cardiovascular MedicinebusinessLipoproteinAngiology
researchProduct

Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect

2020

Liraglutide has shown favourable effects on several cardiometabolic risk factors, beyond glucose control. MicroRNAs (miRNAs) regulate gene expression, resulting in post-transcriptional modifications of cell response and function. Specific miRNAs, including miRNA-27b, miRNA-130a, and miRNA-210, play a role in cardiometabolic disease. We aimed to determine the effect of liraglutide on the serum levels of miRNA-27b, miRNA-130a and miRNA-210. Twenty-five subjects with type-2 diabetes mellitus (T2DM), na&iuml

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and Metabolismlcsh:QR1-502IncretinType 2 diabetestype-2 diabetes030204 cardiovascular system & hematologyBiochemistryArticlelcsh:Microbiologyliraglutide; microRNAs; type-2 diabetes; cardiometabolic risk; epigenetic03 medical and health sciences0302 clinical medicineInterquartile rangeDiabetes mellitusInternal medicinecardiometabolic riskMedicineMolecular Biologyliraglutidebusiness.industryLiraglutideType 2 Diabetes MellitusMicroRNAmedicine.diseaseMetforminmicroRNAs030104 developmental biologyEndocrinologybusinessHomeostasisepigeneticmedicine.drugMetabolites
researchProduct

The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspectives.

2013

Glucagon-like peptide-1 is an incretin secreted in response to nutrient ingestion. Derangements in the incretin system may contribute to the onset and progression of hyperglycemia in Type 2 diabetes. Liraglutide is a long-acting human glucagon-like peptide-1-receptor agonist suitable for once-daily administration. Blood glucose- and weightreducing effects, improvements in pancreatic b-cell function and a low risk of hypoglycemic events have been demonstrated with this agent. There is a trend towards improvement in the proinflammatory milieu. Liraglutide also appears to have beneficial effects on plasma lipids and lipoproteins in the form of a reduction in total cholesterol, triglycerides an…

Agonistmedicine.medical_specialtybusiness.industryLiraglutidemedicine.drug_classCholesterolEndocrinology Diabetes and MetabolismIncretincardiovascular risk diabetes lipids lipoproteins liraglutideType 2 diabetesmedicine.diseaseProinflammatory cytokinechemistry.chemical_compoundEndocrinologychemistryInternal medicineDiabetes mellitusmedicinelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessProspective cohort studymedicine.drug
researchProduct

Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes

2011

Type 2 diabetes is associated with a cluster of inter-related plasma lipid and lipoprotein abnormalities, including reduced HDL-C, a predominance of small, dense LDL and elevated triglycerides. These abnormalities occur even in prediabetes, before blood sugars rise sufficiently in order to confirm a diagnosis of diabetes, and this transition phase incurs important cardiovascular risk. This is the rationale for paying attention to dyslipidemia through the use of the hypolipidemic, rather than hypoglycemic drugs only. A literature search (by Medline and Scopus) was performed. The authors also manually reviewed the references of selected articles for any pertinent material. Beyond the ‘quantit…

medicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismInsulinmedicine.medical_treatmentType 2 diabetesmedicine.diseaseMetformindiabetes LDL size prevention small dense LDL therapyEndocrinologyInternal medicineDiabetes mellitusmedicinelipids (amino acids peptides and proteins)PrediabetesCardiology and Cardiovascular MedicinebusinessPioglitazoneDyslipidemiamedicine.drugLipoproteinClinical Lipidology
researchProduct

Effect of a Natural Supplement Containing Curcuma Longa, Guggul, and Chlorogenic Acid in Patients With Metabolic Syndrome

2015

The impact of a natural supplement (Kepar; Rikrea, Italy), containing several plant extracts such as curcuma longa, silymarin, guggul, chlorogenic acid, and inulin, was evaluated in 78 patients with metabolic syndrome (MetS; 45 men; age: 62 ± 9 years). Kepar at a dose of 2 pills/d was given for 4 months as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study. Anthropometric variables, plasma lipids, glucose parameters, and oxidative stress were measured at baseline and after 4 months. We found significant reductions in body weight (from 81.1 ± 13.5 to 79.4 ± 12.5 kg, P &lt; .0001), body mass index (from 29.6 [23.7] to 29.3 [21.9] kg/m2, P = .001), and wai…

Blood GlucoseMaleTime FactorssilymarinPilot Projectsmedicine.disease_causelaw.inventionchemistry.chemical_compoundlawWeight lossPlant GumsPlant GumCommiphoraCurcuma longainulinbiologyMetabolic Syndrome XMedicine (all)Middle AgedTreatment OutcomeItalyFemalemedicine.symptomCardiology and Cardiovascular MedicineHumanmedicine.medical_specialtyTime Factorchlorogenic acidmetabolic syndromePlant ExtractCurcumaChlorogenic acidguggulInternal medicineWeight LossmedicineHumansPilot ProjectCurcumaAgedDietary Supplementoxidative strePlants MedicinalPlant Extractsbusiness.industryCholesterolcholesterolBiomarkerbiology.organism_classificationmedicine.diseaseWeight LoOxidative Stressnatural supplementEndocrinologychemistryDietary SupplementsMetabolic syndromePhytotherapybusinessBody mass indexBiomarkersOxidative stressPhytotherapyAngiology
researchProduct

Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 D…

2020

Introduction: Liraglutide has several non-glycemic effects, including those on plasma lipids and lipoproteins, contributing to its cardiovascular benefit; however, the exact underlying mechanisms remain unclear. We investigated a novel anti-atherogenic effect of liraglutide in a real-world prospective study on patients with type 2 diabetes (T2DM). Methods: Sixty-two patients with T2DM (31 men, 31 women; mean age ± standard deviation 61 ± 9 years) naïve to incretin-based therapies were treated with liraglutide (1.2 mg/day) as add-on therapy to metformin (1500–3000 mg/day) for 4 months. Laboratory analyses included the assessment of lipoprotein subclass profile by gel electrophoresis (Lipopri…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismLipoproteinsIncretin030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineCardiovascular risk Carotid intima-media thickness Lipoproteins Liraglutide Small dense low-density lipoproteinsType 2 diabetesInternal medicineDiabetes mellitusInternal MedicinemedicineCarotid intima-media thicknessSmall dense low-density lipoproteinsOriginal ResearchLiraglutidebusiness.industryType 2 diabetesLiraglutidemedicine.diseaseCardiovascular riskMetforminEndocrinologyIntima-media thicknessbusinessBody mass indexLipoproteinmedicine.drug
researchProduct

Polyphenols: Potential Use in the Prevention and Treatment of Cardiovascular Diseases

2018

Background: Polyphenols are bioactive compounds that can be found mostly in foods like fruits, cereals, vegetables, dry legumes, chocolate and beverages such as coffee, tea and wine. They are extensively used in the prevention and treatment of cardiovascular disease (CVD) providing protection against many chronic illnesses. Their effects on human health depend on the amount consumed and on their bioavailability. Many studies have demonstrated that polyphenols have also good effects on the vascular system by lowering blood pressure, improving endothelial function, increasing antioxidant defences, inhibiting platelet aggregation and low-density lipoprotein oxidation, and reducing inflammator…

0301 basic medicinePolyphenolcardiovascular risklignanAntioxidantmedicine.medical_treatmentInflammationPharmacologystilbenesmedicine.disease_cause03 medical and health sciencespreventionDiabetes mellitusDrug DiscoveryHumansMedicineAnimalsflavonoidLipoprotein oxidationEndothelial dysfunctionpolyphenolsPharmacologytherapytherapy.030109 nutrition & dieteticsphenolic acidbusiness.industrylignansfood and beveragesmedicine.diseasestilbeneCardiovascular DiseasesPolyphenolflavonoidspolyphenols; flavonoids; lignans; stilbenes; phenolic acids; prevention; therapy; cardiovascular riskmedicine.symptombusinessphenolic acidsOxidative stressLipoprotein
researchProduct

MALIGNANT TUMOR-LIKE GAASTRIC LESION DUE TO CANDIDA ALBICANS IN A DIABETIC PATIENT TREATED WITH CYCLOSPORIN: A CASE REPORT AND REVIEW OF THE LITERATU…

2012

The gastrointestinal tract of healthy individuals is colonized by hundreds of saprophytes and mycetes, especially the Candida species, are habitual ones. Under certain conditions, the fungal flora may overgrow, resulting in lesions of the digestive mucosa which, rarely, can have a local diffusion and/or spread to the lympho-hematogenous system. Mycotic infections of the stomach can sometimes look like benign gastric ulcers. Here, we present the case report of a woman, aged 64, who presented with type II diabetes mellitus and psoriasis, on chronic treatment with cyclosporin A and with endoscopic evidence of an ulcerated, vegetating gastric lesion secondary to Candida albicans infection. Alth…

Pathologymedicine.medical_specialtyAntifungal AgentsSettore MED/09 - Medicina InternaSettore MED/08 - Anatomia PatologicaMalignancyGastroenterologyGeneral Biochemistry Genetics and Molecular BiologyCyclosporin aDiabetes mellitusInternal medicinePsoriasisCandida albicansCandidiasis Mycotic infection of the gastrointestinal tract submucosal tumorHumansMedicineStomach UlcerCandida albicansGastrointestinal tractHematologybiologybusiness.industryStomachCandidiasisGeneral MedicineMiddle Agedbiology.organism_classificationmedicine.diseaseSettore MED/18 - Chirurgia Generalemedicine.anatomical_structureDiabetes Mellitus Type 2CyclosporineFemaleItraconazolebusiness
researchProduct

Oxidative stress and small, dense low-density lipoproteins: current and future perspectives

2019

Small, dense low-density lipoproteins (LDLs) are more susceptible to oxidation than their larger, more buoyant counterparts and therefore the biological modification of these LDL particles may, in part, be responsible for their atherogenic properties. Kotani et al. found that at multiple regression analysis there was an independent and significant inverse correlation between the mean LDL particle size and the oxidative stress status; notably, the authors adjusted not only for the traditional cardiovascular risk factors, but also for drug treatments. Higher levels of small, dense LDL concentrations significantly contribute to atherosclerosis, and lipoprotein size and subfractions may refine …

cardiovascular riskoxidative stremedicine.medical_specialtySmall dense ldldense LDLEndocrinology Diabetes and Metabolismdyslipidemiasmallmedicine.diseasemedicine.disease_causechemistry.chemical_compoundEndocrinologylow-density lipoproteinchemistryInternal medicineLow-density lipoproteinmedicineLow densityDisease risklipids (amino acids peptides and proteins)Inverse correlationDyslipidemiaOxidative stressLipoproteinExpert Review of Endocrinology &amp; Metabolism
researchProduct

Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes

2022

The current management of Type 2 Diabetes Mellitus (T2DM) includes incretin-based treatments able to enhance insulin secretion and peripheral insulin sensitivity as well as improve body mass, inflammation, plasma lipids, blood pressure, and cardiovascular outcomes. Dietary Free Fatty Acids (FFA) regulate metabolic and anti-inflammatory processes through their action on incretins. Selective synthetic ligands for FFA1-4 receptors have been developed as potential treatments for T2DM. To comprehensively review the available evidence for the potential role of FFA receptor agonists in the treatment of T2DM, we performed an electronic database search assessing the association between FFAs, T2DM, i…

cardiovascular riskMedicine (General)Cardiovascular risk Free fatty acidsGLP-1 Incretins Metabolism Type 2 diabetes Fatty Acids Nonesterified Humans Diabetes Mellitus Type 2 Insulin Resistanceendocrine system diseasesfree fatty acidsType 2 diabetesReviewGeneral MedicineFatty Acids NonesterifiedR5-920Diabetes Mellitus Type 2HumansInsulin ResistanceGLP-1metabolismincretinsMedicina
researchProduct

Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: An 8-month prospective pi…

2015

Objective: To explore the effects of the glucagon-like peptide-1 receptor analogue liraglutide on subclinical atherosclerosis in diabetic subjects with non-alcoholic fatty liver disease (NAFLD).Research design and methods: In this 8-month prospective study, 29 subjects with type 2 diabetes (T2DM) and NAFLD (16 men and 13 women, mean age: 61 ± 10 years) were matched for age and gender with 29 subjects with T2DM without NAFLD (16 men and 13 women, mean age: 61 ± 8 years). Liraglutide 0.6 mg/day for 2 weeks, followed by 1.2 mg/day, was given in addition to metformin.Main outcome measures: Anthropometric variables, glucometabolic parameters and carotid intima-media thickness (IMT) using B-mode …

MaleClinical BiochemistryPilot ProjectsType 2 diabetesCarotid Intima-Media ThicknessGastroenterologychemistry.chemical_compoundRisk FactorsDrug DiscoveryProspective StudiesProspective cohort studyliraglutideMedicine (all)Fatty liverLipidMiddle AgedLipidsHemoglobin AAtherosclerosiFemalemedicine.drugHumanmedicine.medical_specialtycarotid intima-media thickneInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsPilot ProjectAgedGlycated HemoglobinHemoglobin A GlycosylatedPharmacologytype 2 diabeteHypoglycemic AgentLiraglutidebusiness.industryRisk FactorDrug Discovery3003 Pharmaceutical Sciencenutritional and metabolic diseasesnon-alcoholic fatty liver diseaseAtherosclerosismedicine.diseaseProspective StudieEndocrinologychemistryIntima-media thicknessDiabetes Mellitus Type 2Glycated hemoglobinbusiness
researchProduct

Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospectiv…

2016

Abstract Background Liraglutide, a GLP-1 analogue, exerts several beneficial non-glycemic effects in patients with type-2 diabetes (T2DM), such as those on body weight, blood pressure, plasma lipids and inflammation markers. However, the effects of liraglutide on cardiovascular (CV) risk markers in subjects with the metabolic syndrome (MetS) are still largely unknown. We herein explored its effects on various cardio-metabolic risk markers of the MetS in subjects with T2DM. Methods We performed an 18-month prospective, real-world study. All subjects had T2DM and the MetS based on the AHA/NHLBI criteria. Subjects with a history of a major CV event were excluded. One hundred-twenty-one subject…

Carotid Artery DiseasesMaleEndocrinology Diabetes and MetabolismPredictive Value of Test030204 cardiovascular system & hematologyCarotid intima-media thickne0302 clinical medicineRisk FactorsPrevalenceProspective StudiesCarotid intima-media thicknessProspective cohort studyOriginal Investigation2. Zero hungerIncretinMiddle AgedMetabolic syndromeMetformin3. Good healthMetforminTreatment OutcomeItalyCardiologyDrug Therapy CombinationFemaleCardiology and Cardiovascular MedicineHumanmedicine.drugmedicine.medical_specialtyIncretin030209 endocrinology & metabolismIncretins03 medical and health sciencesPredictive Value of TestsInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsCardiovascular risk Carotid intima-media thickness Liraglutide Metabolic syndromeAgedCarotid Artery DiseaseHypoglycemic AgentLiraglutidebusiness.industryRisk FactorBiomarkerLiraglutideCardiovascular riskmedicine.diseaseEchocardiography Doppler ColorProspective StudieDiabetes Mellitus Type 2Intima-media thicknessMetabolic syndromebusinessBody mass indexBiomarkersCardiovascular Diabetology
researchProduct

Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation

2013

Incretin peptides are a group of gastrointestinal hormones that play a prominent role in the regulation of glucose metabolism. Incretin-based therapies (IBTs) have recently emerged as an important treatment option for patients with type 2 diabetes mellitus (T2DM). These pharmaceutical agents may be specially well suited for patients who are overweight or obese with primarily post-meal glucose peaks, and in whom traditional first-line oral agents have failed to maintain adequate glycemic control. There are 2 classes of IBTs: the dipeptidyl peptidase-4 (DPP-4) inhibitors and the glucagon-like peptide 1 (GLP-1) receptor agonists. The ultimate effect of both types of agents is to augment GLP-1 …

medicine.medical_specialtyLipoproteinsIncretin type 2 diabetes mellitus metabolic syndrome lipoproteinsIncretinBiologyIncretinsGlucagon-Like Peptide-1 ReceptorWeight lossDiabetes mellitusInternal medicineDrug DiscoverymedicineAnimalsHumansGlucose homeostasisAdiponectin secretionLipoproteinInflammationPharmacologyDipeptidyl-Peptidase IV InhibitorsDrug Discovery3003 Pharmaceutical ScienceMedicine (all)digestive oral and skin physiologyGlucagon secretionType 2 Diabetes MellitusIncretinAtherosclerosismedicine.diseaseMetabolic syndromeType 2 diabetes mellituGlucoseEndocrinologyDiabetes Mellitus Type 2Metabolic syndromemedicine.symptomCurrent Pharmaceutical Design
researchProduct

Management of Statin Intolerance in 2018: Still More Questions Than Answers.

2018

Statin therapy is generally well tolerated and very effective in the prevention and treatment of cardiovascular disease, regardless of cholesterol levels; however, it can be associated with various adverse events (myalgia, myopathy, rhabdomyolysis, and diabetes mellitus, among others). Patients frequently discontinue statin therapy without medical advice because of perceived side effects and consequently increase their risk for cardiovascular events. In patients with statin intolerance, it may be advisable to change the dose, switch to a different statin, or try an alternate-day regimen. If intolerance is associated with all statins—even at the lowest dose—non-statin drugs and certain nutra…

myalgiamedicine.medical_specialtyStatinDrug-Related Side Effects and Adverse Reactionsmedicine.drug_classDiseaseReview Article030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePharmacotherapyMedical adviceDiabetes mellitusCardiovascular DiseasemedicineHumansPharmacology (medical)030212 general & internal medicinecardiovascular diseasesAdverse effectIntensive care medicineDietary SupplementHypolipidemic AgentsHypolipidemic Agentbusiness.industrynutritional and metabolic diseasesDisease ManagementGeneral MedicineCholesterol LDLmedicine.diseaseRegimenCardiovascular DiseasesDietary Supplementslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitormedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessDrug-Related Side Effects and Adverse ReactionHumanAmerican journal of cardiovascular drugs : drugs, devices, and other interventions
researchProduct

Pasta Supplemented with Opuntia ficus-indica Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Pa…

2020

Food supplementation with Opuntia ficus-indica (OFI) has been associated with a significant reduction in total cholesterol, body fat, hyperglycemia and blood pressure. Since OFI may also have antioxidant and anti-atherogenic properties, we hypothesized that its supplementation might reduce atherogenic lipoproteins, including small, dense low-density lipoproteins (sdLDL). Forty-nine patients (13 men and 36 women, mean age: 56 &plusmn

0301 basic medicinecardiovascular riskmedicine.medical_specialtyOpuntia ficus-indicaAntioxidantWaistEndocrinology Diabetes and Metabolismmedicine.medical_treatmentlcsh:QR1-502Aspartate transaminase030204 cardiovascular system & hematologyPolysaccharideBiochemistrylcsh:MicrobiologyArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineMolecular Biologychemistry.chemical_classificationnutraceuticalslow-density lipoprotein cholesterol030109 nutrition & dieteticsbiologybusiness.industrydyslipidemiamedicine.disease<i>Opuntia ficus-indica</i>EndocrinologyBlood pressurechemistryUreabiology.proteinMetabolic syndromebusinessDyslipidemia
researchProduct

Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An …

2019

AIM: To evaluate the effect of exenatide long acting release (LAR) on carotid intima-media thickness (IMT) and endothelial function in patients with type 2 diabetes mellitus. METHODS: Sixty subjects with type 2 diabetes mellitus were treated with exenatide LAR as add-on to stable doses of metformin for 8 months in an open label study. Anthropometric variables, lipid profile and glycemic parameters were assessed by routine analysis. Carotid IMT by Doppler ultrasound and endothelial function by flow-mediated dilation of the brachial artery were also assessed. RESULTS: Exenatide significantly improved fasting glycaemia (from 8.8 ± 2.8 to 7.3 ± 2.2 mmol/L, p &lt; 0.0001), HbA1c (from 8.0 ± 0.4 …

Malemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetesCarotid Intima-Media ThicknessCarotid intima-media thickne03 medical and health sciences0302 clinical medicineEndocrinologyRisk FactorsInternal medicineDiabetes mellitusInternal MedicineMedicineHumansHypoglycemic Agentscardiovascular diseases030212 general & internal medicineProspective StudiesEndothelial dysfunctionmedicine.diagnostic_testbusiness.industryType 2 Diabetes MellitusGeneral MedicineMiddle Agedmedicine.diseaseCardiovascular diseaseAtherosclerosisMetforminIntima-media thicknessDiabetes Mellitus Type 2Atherosclerosicardiovascular systemCardiologyExenatideFemalebusinessLipid profileExenatidemedicine.drugDiabetes research and clinical practice
researchProduct

Anti-atherogenic Effects of 17β-Estradiol

2013

Estrogens are secreted primarily by the ovaries and placenta, by the testes in men and also produced by peripheral steroidogenic conversion. The 3 major naturally occurring estrogens are: 17β-estradiol (E2), estrone and estriol, of which E2 is the predominant and most active. The actions of E2 are mediated by at least 3 different receptors - the classical ERs (ERα and ERβ) and G-protein coupled receptor 30 (GPR30). E2 signaling in cardiomyocytes involves ERα- and ERβ-independent pathways, and treatment with the E2 receptor antagonists (Selective Estrogen Receptor Modulators- SERMs), which are agonists of GPR30, inhibits cardiac cell growth. Effects of E2 in preventing endothelial dysfunctio…

MaleSelective Estrogen Receptor Modulatorsmedicine.medical_specialtyVascular smooth muscleEndotheliummedicine.drug_classEndocrinology Diabetes and MetabolismOvariectomyClinical BiochemistryInflammation030204 cardiovascular system & hematologyBiologyBiochemistry03 medical and health sciencesestrogen 17β-estradiol atherogenic factors atherosclerosis0302 clinical medicineEndocrinologyRisk FactorsInternal medicinemedicineAnimalsHumansEndothelial dysfunctionReceptorEstradiolBiochemistry (medical)Estrogen Replacement TherapyGeneral Medicinemedicine.diseaseAtherosclerosis3. Good healthmedicine.anatomical_structureEndocrinologySelective estrogen receptor modulatorEstrogen030220 oncology & carcinogenesisDiet AtherogenicFemalemedicine.symptomGPER
researchProduct

An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes.

2022

Guidelines have increasingly stressed the concept that adequate glycemic control is required to prevent or decrease the macro- and microvascular complications of type 2 diabetes mellitus (T2DM). PPAR-gamma agonists (“glitazones”) are no longer prioritized due to their effects on heart failure. However, the association between these drugs and innovative therapies could be a valuable tool to attenuate the risk factors of the metabolic syndrome. Glitazones are used for the treatment of diabetes and associated comorbidities. There is substantial scientific evidence demonstrating the effect of glitazones at a cardiometabolic level, as well as on hematological and neurological pathologies that po…

RosiglitazoneDiabetes Mellitus Type 2PioglitazonePeroxisome Proliferator-Activated ReceptorsHumansHypoglycemic AgentsThiazolidinedionescardiovascular risk metabolic syndrome pioglitazone type 2 diabetes mellitusGeneral MedicineMedicina (Kaunas, Lithuania)
researchProduct

Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory …

2020

Extra virgin olive oil (EVOO) intake is associated with reduced cardiovascular risk, and its phenolic compound oleocanthal (OC) has anti-oxidant and anti-inflammatory properties. The cardiometabolic effects of EVOO with a high OC concentration have not been fully elucidated. We administered EVOO with a high OC concentration daily to 23 subjects with the metabolic syndrome (MetS) and hepatic steatosis (15 men and 8 women, age: 60 &plusmn

Polyphenolmedicine.medical_specialtyWaistEndocrinology Diabetes and Metabolismlcsh:QR1-502030204 cardiovascular system & hematologyBiochemistryArticlemetabolic syndromeoleocanthallcsh:Microbiology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineOleocanthalmedicineIngestion030212 general & internal medicineMolecular BiologyCytokinepolyphenolsbiologybusiness.industryFatty liverCytokines metabolic syndrome oleocanthal olive oil polyphenols.medicine.diseaseolive oilcytokinesEndocrinologychemistryAlanine transaminasebiology.proteinSteatosisMetabolic syndromebusinessBody mass indexMetabolites
researchProduct

Metabolic disorders during pregnancy and postpartum cardiometabolic risk

2018

Hormonal changes during pregnancy can trigger gestational diabetes (GDM), which is constantly increasing. Its main characteristic is pronounced insulin resistance, but it appears to be a multifactorial process involving several metabolic factors; taken together, the latter leads to silent or clinically evident cardiovascular (CV) events. Insulin resistance and central adiposity are of crucial importance in the development of metabolic syndrome, and they appear to correlate with CV risk factors, including hypertension and atherogenic dyslipidaemia. Hypertensive disease of pregnancy (HDP) is more likely to be an accompanying co-morbidity in pregnancies complicated with GDM. There is still inc…

cardiovascular riskhypertensionOffspringEndocrinology Diabetes and MetabolismPhysiology030209 endocrinology & metabolism030204 cardiovascular system & hematologylcsh:Diseases of the endocrine glands. Clinical endocrinologymetabolic syndrome03 medical and health sciences0302 clinical medicineEndocrinologyInsulin resistanceInternal MedicinemedicineCardiometabolic riskPregnancylcsh:RC648-665business.industrymedicine.diseaseGestational diabetesEditorialGestational diabeteHypertensive disease of pregnancygestational diabetesMetabolic syndromebusinessHormoneEndocrine Connections
researchProduct

Elevated blood Hsp60, its structural similarities and cross-reactivity with thyroid molecules, and its presence on the plasma membrane of oncocytes p…

2014

The role Hsp60 might play in various inflammatory and autoimmune diseases is under investigation, but little information exists pertaining to Hashimoto’s thyroiditis (HT). With the aim to fill this gap, in the present work, we directed our attention to Hsp60 participation in HT pathogenesis. We found Hsp60 levels increased in the blood of HT patients compared to controls. The chaperonin was immunolocalized in thyroid tissue specimens from patients with HT, both in thyrocytes and oncocytes (Hurthle cells) with higher levels compared to controls (goiter). In oncocytes, we found Hsp60 not only in the cytoplasm but also on the plasma membrane, as shown by double immunofluorescence performed on …

MaleIntegrinsmedicine.medical_treatmentThyroid Glandmedicine.disease_causeBiochemistryThyroiditisAutoimmunityHashimoto DiseaseThyroglobulin (TG)Hashimoto's thyroiditis (HT)Oxyphil CellsbiologyThyroid peroxidase (TPO)GoiterThyroidHsp60Immunohistochemistrymedicine.anatomical_structureFemaleAntibodyAdultmedicine.medical_specialtyendocrine systemanimal structuresMolecular Sequence Datachemical and pharmacologic phenomenaEnzyme-Linked Immunosorbent AssayHashimoto DiseaseCross Reactionscomplex mixturesIodide PeroxidaseThyroglobulinMitochondrial ProteinsYoung AdultThyroid peroxidaseInternal medicinemedicineHumansAmino Acid SequenceAutoantibodiesOriginal PaperfungiCell MembraneAutoantibodyComputational BiologyCell BiologyChaperonin 60medicine.diseaseHsp60 . Hashimoto's thyroiditis (HT) . Thyroglobulin (TG) . Thyroid peroxidase (TPO) . Autoantibodies . Oncocytes . Hurthle cells . Thyrocytes . Chaperonin . AutoimmunityEndocrinologyStructural Homology Proteinbiology.proteinLeukocytes MononuclearThyroglobulinCell stresschaperones
researchProduct

The Role of Nutraceuticals in Statin Intolerant Patients.

2018

Abstract Statins are the most common drugs administered for patients with cardiovascular disease. However, due to statin-associated muscle symptoms, adherence to statin therapy is challenging in clinical practice. Certain nutraceuticals, such as red yeast rice, bergamot, berberine, artichoke, soluble fiber, and plant sterols and stanols alone or in combination with each other, as well as with ezetimibe, might be considered as an alternative or add-on therapy to statins, although there is still insufficient evidence available with respect to long-term safety and effectiveness on cardiovascular disease prevention and treatment. These nutraceuticals could exert significant lipid-lowering activ…

Statinmedicine.drug_classDiseasecardiovascular risk ; dyslipidemia ; nutraceuticals ; position paper ; statin intolerance030204 cardiovascular system & hematologyBioinformaticsKlinikai orvostudományok03 medical and health sciences0302 clinical medicineNutraceuticalEzetimibeStatin intoleranceRed yeast riceMedicineHumansPosition paper030212 general & internal medicineEndothelial dysfunctionDyslipidemiasbusiness.industryClinical Studies as TopicOrvostudományokmedicine.diseaseCardiovascular risk3. Good healthDyslipidemiaDietary SupplementsArterial stiffnesslipids (amino acids peptides and proteins)nutraceuticalHydroxymethylglutaryl-CoA Reductase InhibitorNutraceuticalsHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessDyslipidemiaposition papermedicine.drugstatin intoleranceHuman
researchProduct

Food hypersensitivity in patients with irritable bowel syndrome: the diagnostic role of fecal assays.

2011

Food hypersensitivitySettore MED/09 - Medicina Internafecal assaysirritable bowel disease
researchProduct

Cloni di carciofo "Romanesco" in coltura annuale in Sicilia

2012

Valutation of “Romanesco” artichoke clones in Sicily The artichoke is one of the most important vegetables cultivated in Sicily, especially for small and medium sized farms. The artichoke in Sicily is represented mostly by local ecotypes and varieties that go into production in autumn, which is most appreciated by consumers in the south. But they have lower production and are less homogeneous than spring varieties. In recent years, agricultural techniques for propagation, fertilization and disease control for the autumn artichokes have improbe considerably, but less for the selection of different cultivars, in particular with the spring varieties. The introduction of the spring cultivars wo…

RomanecoGA3Settore AGR/04 - Orticoltura E FloricolturaCarciofo
researchProduct

Rare Candida albicans overgrowth in an immunosuppressed patient: case report of a malignant tumor-like gastric lesion.

2011

Candida albicantumor-like gastric lesion
researchProduct

Lichen sclerosus and atrophicus: report of a case of female patient affected with recurrent cystitis.

2011

Lichen sclerosus recurrent cystitis
researchProduct

Gli effetti extraglicemici di liraglutide: Focus sui marker cardiometabolici

2016

The purpose of innovative therapeutic approaches for type 2 diabetes mellitus is to customize the antidiabetic treatment to each patient's need, in order to intensify glucose-lowering effects without hypoglycemia, reduce adverse events, and prevent cardiovascular events. Glucagon-like peptide 1 (GLP-1) analogues are effective drugs in the treatment of type 2 diabetes, and they also seem to have beneficial effects on several risk factors for cardiovascular disease, leading to cardiovascular risk reduction independent of hypoglycemic effects. Among these new drugs, liraglutide, a GLP-1 analogue with a homology of 97% to native GLP-1, exerts an effect on body weight, lipid parameters, blood pr…

Carotid intima-media thickneType 2 diabetes mellituLiraglutideCardiovascular riskCardiology and Cardiovascular MedicineCardiometabolic marker
researchProduct

Effects of Liraglutide on Carotid Intima-Media Thickness in Patients with Type-2 Diabetes and Non-Alcoholic Fatty Liver Disease: An 8-Month Prospecti…

2014

Liraglutide Carotid Intima-Media Thickness Type-2 Diabetes Non-Alcoholic Fatty Liver DiseaseSettore MED/09 - Medicina Interna
researchProduct

Serological, immunomorphological and bioinformatics analyses suggest Hsp60 is involved in Hashimoto’s thyroiditis pathogenesis.

2013

Immunomodulation Hsp60
researchProduct

Lichen sclerosus as a cause of recurrent cystitis: case report and review of the literatury.

2012

lichen sclerosuSettore MED/09 - Medicina Internacystitislichen sclerosus; cystitis
researchProduct

Improving diagnostic accuracy in Celiac Disease diagnosis: anti-endomysium antibody assay in colture medium of duodenal biopsies.

2011

Celiac DiseaseSettore MED/09 - Medicina Internaduodenal biopsiesanti-endomysium antibody
researchProduct

Prediction of vascular events in subjects with subclinical atherosclerosis and the metabolic syndrome: the role of markers of inflammation.

2010

vascular events atherosclerosis the metabolic syndrome inflammation
researchProduct

Malignant tumor-like gastric lesion by Candida albicans.

2011

Candida albicandiabetes cyclosporin A
researchProduct

Variazioni emodinamiche del circolo epatico in pazienti con bright liver ecopattern e sindrome metabolica

2007

researchProduct

PREVALENCE OF LIVER STEATOSIS AND FIBROSIS AND RELIABILITY OF ULTRASOUND IN DETECTING NAFLD IN OBESE PATIENTS

2018

Background: Non-alcoholic fatty liver disease (NAFLD) is the most frequent chronic liver disease in Western countries, and in particular in obese patients the prevalence is higher than in general population. It has a large clinical spectrum, ranging from simple steatosis to steatohepatitis (NASH) and cirrhosis. Aim of the study: To evaluate in obese patients who underwent bariatric surgery in the last 3 years: 1) the histological prevalence and severity of liver steatosis (LS) and fibrosis; 2) the reliability of ultrasound (US) in diagnosing steatosis. Patients and methods: We reviewed preoperative liver US and intraoperative liver biopsy results in 57 bariatric surgery patients (age 42 ± 1…

Settore MED/09 - Medicina InternaLIVER STEATOSIS FIBROSIS ULTRASOUND NAFLD SEVERE OBESITY BARIATRIC SURGERY
researchProduct

Prevalence of antibodies anti-bartonella henselae in western Sicily: children, blood donors, cats

2011

cat scratch diseaseBartonella
researchProduct

Improving diagnostic accuracy in celiac disease diagnosis: antiendomysium antibody assay in the culture medium of duodenal biopsies.

2011

duodenal biopsiesCeliac disease
researchProduct

Autoimmune liver disease in a sicilian woman.

2012

Autoimmune hepatitis (AIH) is a chronic liver disease characterized by clinical features analogue to viral and non-autoimmune liver disorders, but with distinct sero-autoimmunologic properties. The disease results from a network of complex interactions involving genetic predisposition, triggering factors, autoantigens and immunoregulatory system. Diagnosis of AIH relies on positive autoantibodies determination and on liver core biopsy histological appearance. Corticosteroid and immunosuppressive drugs are generally useful in the treatment of disease. However, when inflammation cannot be controlled, progression from chronic hepatitis to cirrhosis is often observed and hepatocellular carcinom…

Settore MED/09 - Medicina InternaAutoimmune liver disease
researchProduct

Food hypersensitivity-associated irritable bowel syndrome: may fecal assays improve diagnosis?

2011

Food hypersensitivityfecal assays
researchProduct

Diagnostica non invasiva delle varici esofagee nei pazienti con cirrosi epatica: dati ecografici vs dati endoscopici

2008

The aim of this study was to identify possible clinical, biochemical or instrumental markers which can predict in a non-invasive manner the presence of EV. One hundred and fifty-eight consecutive liver cirrhotic patients seen at our outpatient clinic were included in this study. The diagnosis of LC was done on liver biopsy findings or based on instru m e n t a l , clinical and serological data. Patients underwent EGE, ultra - sound of the upper abdomen, Doppler of the main splancnic vessels and the main parameters of liver function were tested. Liver cirrhosis was mostly correlated to hepatitis C virus and most patients were class A according to Child. At EGE, EV w e re absent in 41 patient…

Liver cirrhosis esophageal varices ultrasound esophago-gastro-duodenoscopy portal hypertension
researchProduct

Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients With Type 2 D…

2020

Article full text The article associated with this page has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on this page in the next few days. The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite). © The authors, CC-BY-NC 2020.

researchProduct